Abstracts tagged "B cells"

Abstract Number: 2577 • 2012 ACR/ARHP Annual Meeting
Characterization of Circulating Human B Cells That Bind Cyclic Citrullinated Peptide Antigens in Clinically Active Rheumatoid Arthritis
Gregg J. Silverman¹, John Jung², Jeffrey D. Greenberg³, Adam J. Pelzek⁴, Caroline Gronwall⁵ and Jaya Vas⁵, ¹Medical and Pathology, NYU School of Medicine, New York, NY, ²School of Medicine, NYU, New York, NY, ³New York Hospital for Joint Disease, New York, NY, ⁴School of Medicine, NYU School of Medicine, New York, NY, ⁵Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) were first identified based on their high specificity for RA and now are commonly used as a diagnostic tool. Yet,…
Abstract Number: 1764 • 2012 ACR/ARHP Annual Meeting
B Cells in Early Rheumatoid Arthritis: ZAP-70 More Than SYK Characterize Seropositive Disease
Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Laura Bosello, Angela Carbonella, Silvia Canestri and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: B cells are involved as central players in the pathogenesis of rheumatoid arthritis (RA). Our aim was to define whether a specific B cell…
Abstract Number: 1457 • 2012 ACR/ARHP Annual Meeting
A Novel Small Molecular Anti-Rheumatic Drug, T-614, Ameliorates Lupus-Like Disease in MRL/Lpr Mice by Suppressing B Cell Functions
Qingran Yan¹, Fang Du² and Chunde Bao², ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Rheumatology, Renji Hospital, Shanghai, China
Background/Purpose: T-614 is a small molecular drug that has multiple immunomodulatory effects and has been used for treating rheumatoid arthritis. Previous work has revealed this…
Abstract Number: 509 • 2012 ACR/ARHP Annual Meeting
IL-7 and Toll-Like Receptor 7 Synergistically Increase Th1/Th17/Th22 Cytokine Secretion and Activity of B Cells
A. Bikker¹, A.a. Kruize¹, F. Redegeld², W. de Jager³, F.P.J.G. Lafeber⁴ and J.A.G. van Roon⁵, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Dept Pharmacology UU, Utrecht, Netherlands, ³Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: IL-7 is a potent T cell activating cytokine that has been shown to cause proliferation, survival and differentiation of T cells as well as…
Abstract Number: 2578 • 2012 ACR/ARHP Annual Meeting
Monoclonal IgG Antibodies (ACPAs) From Synovial Fluid B Cells of Rheumatoid Arthritis Patients – Antigen-Driven Affinity Maturation and Cross Reactivity
Khaled Amara¹, Johanna Steen², Fiona Murray², Henner Morbach³, Blanca Fernandez-Rodriguez⁴, Vijay Balasingh², Marianne Engström², Omri Snir², Lena Israelsson⁵, Anca Catrina², Hedda Wardemann⁶, Davide Corti⁴, Eric Meffre Sr.³, Lars Klareskog⁷ and Vivianne Malmström⁸, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE-17176 Solna, Stockholm, Sweden., Stockholm, Sweden, ²Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Department of Immunobiology, Yale University School of Medicine, New Haven, CT, ⁴Institute for Research in Biomedicine, Bellinzona, Switzerland, ⁵Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁶Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Antibodies targeting citrullinated proteins (ACPA) are commonly found in patients with Rheumatoid Arthritis (RA), strongly associate with distinct HLA-DR alleles and predict a more…
Abstract Number: 1765 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Is Associated with Signaling Alterations in Naturally Occurring Autoreactive B-Lymphocytes
Taras Lyubchenko¹, Ganna Liubchenko², Holly C. Appleberry², Christopher C. Striebich², Karen E. Franklin², Lezlie A. Derber³ and V. Michael Holers⁴, ¹Medicine, University of Colorado Denver, Aurora, CO, ²University of Colorado Denver, Aurora, CO, ³Division of Rheumatology, University of Colorado Denver, Aurora, CO, ⁴Rheumatology Division, University of Colorado Denver, Aurora, CO
Background/Purpose: Alterations in B cell immune tolerance are important in the development of autoimmune rheumatoid arthritis (RA). Recent studies in healthy human subjects have identified…
Abstract Number: 1450 • 2012 ACR/ARHP Annual Meeting
MEDI-551 Depletes a Majority of Murine B Cells and Reduces Serum Titers of Autoantibodies in the SLE1-huCD19 TG Mice
Sandra Gallagher¹, Yue Wang¹, Isharat Yusuf¹, Thomas McCaughtry¹, Ronald Herbst² and Laura Carter¹, ¹Respiratory, Inflammation and Autoimmune, MedImmune, Gaithersburg, MD, ²Respiration, Inflammation and Autoimmunity, MedImmune, Gaithersburg, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by chronic inflammation that can affect various organs. Hyperactive B cells appear to be key drivers in SLE…
Abstract Number: 482 • 2012 ACR/ARHP Annual Meeting
B-Lymphocyte Count Is Not Associated with an Increased Risk of Infection in Patients Treated with Rituximab for Auto-Immune Diseases
Ilias Lazarou¹, Axel Finckh², Lara Fischer³, Camillo Ribi³, Joerg Seebach³ and Pierre A. Guerne², ¹University Hospitals of Geneva, Geneva, Switzerland, ²Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ³Immunology, University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: B-Lymphocyte (B-Ly) depletion therapy with the monoclonal anti-CD20 antibody rituximab (RTX) is widely used in a variety of autoimmune (AI) diseases. The risk of…
Abstract Number: 2529 • 2012 ACR/ARHP Annual Meeting
Molecular Mechanism of IgG4 Class Switch Recombination in IgG4-Related Disease
Hiroto Tsuboi¹, Mana Iizuka¹, Hiromitsu Asashima¹, Sayaka Tsuzuki¹, Yuya Kondo¹, Akihiko Tanaka², Masafumi Moriyama², Isao Matsumoto¹, Seiji Nakamura² and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Faculty of Dental Science, Kyushu University, Fukuoka, Japan
Background/Purpose: IgG4-related disease (IgG4-RD) is a new disease entity characterized by high serum IgG4 levels, IgG4-positive plasmacytic infiltration and fibrosis in various organs. Although the…
Abstract Number: 1767 • 2012 ACR/ARHP Annual Meeting
Circulating Plasmablasts As a Source of Anti-Citrullinated Protein Antibodies in Patients with Rheumatoid Arthritis
Priscilla Kerkman, Ellen I.H. van der Voort, Leendert A. Trouw, Tom W.J. Huizinga, René E.M. Toes and Hans Ulrich Scherer, Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti citrullinated protein antibodies (ACPA) are highly specific for rheumatoid arthritis (RA) and predict disease onset and severity. Accumulating evidence indicates that ACPA could…
Abstract Number: 1207 • 2012 ACR/ARHP Annual Meeting
Impact of Anti Tumor Necrosis Factor-Alpha Therapy in Rheumatoid Arthritis On Osteoclast Activation and B Cells
Ezinma Ezealah¹, Jennifer Hossler¹, Jamie Biear¹, Christopher A. Cistrone¹, Teresa Owen¹, Nida Meednu¹, Kelly Callahan¹, Arumugam Palanichamy¹, Ignacio Sanz², Allen P. Anandarajah¹, Ralf G. Thiele¹, Darren Tabechian³, R. John Looney¹ and Jennifer H. Anolik¹, ¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Rheumatology, Emory University, Atlanta, GA, ³Allergy/Immun/Rheumatology, Univ of Rochester Schl of Med, Rochester, NY
Background/Purpose: Serum receptor activator of NFkB ligand (RANKL) and its natural decoy receptor, osteoprotegerin (OPG), play key roles in osteoclast activation. In a group of…
Abstract Number: 316 • 2012 ACR/ARHP Annual Meeting
The Interleukin-10 (IL-10) Producing Regulatory B Cell (“B10 cell”) Compartment Expands with Disease Activity in Juvenile Dermatomyositis (JDM) and Pediatric-Onset Systemic Lupus Erythematosus (pSLE)
Ioannis Kalampokis¹, Jeffrey A. Dvergsten² and Thomas Tedder³, ¹Immunology and Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ²Pediatrics Division of Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ³Department of Immunology, Duke University Medical Center, Durham, NC
Background/Purpose: pSLE and JDM are multisystem inflammatory diseases, whereas juvenile idiopathic arthritis (JIA) is typically an organ-limited disease. “B10 cells”, a rare subset of human…
Abstract Number: 2453 • 2012 ACR/ARHP Annual Meeting
The Role of Bob1 in Rheumatoid Arthritis: Potential Implications for Autoimmunity
Nataliya Yeremenko¹, Tineke Cantaert¹, Melissa N. van Tok², Ioana Gofita¹, Juan D. Canete³, Paul P. Tak⁴, Hergen Spits⁵ and Dominique L. Baeten⁴, ¹Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ³Arthritis Unit. Rheumatology Department, Hospital Clínic, Barcelona, Spain, ⁴Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Tytgat Institute for Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a prototypic autoimmune disease characterized by a prominent humoral autoimmunity. Of particular relevance is the local production of autoantibodies such…
Abstract Number: 1774 • 2012 ACR/ARHP Annual Meeting
Identification of Target Antigens of Anti-Endothelial Cell Antibodies in Patients with ANCA-Associated Systemic Vasculitis: A Proteomic Approach
Alexis Régent¹, Hanadi Dib², Guillaume Bussone¹, Mathieu C. Tamby¹, Nicolas Tamas², Christian Federici³, Cédric Broussard³, Loic Guillevin⁴ and Luc Mouthon¹, ¹Internal Medicine, Hopital Cochin, Paris, France, ²Université Paris Descartes, Paris, France, ³Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Paris, France, ⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Anti-endothelial cell antibodies (AECA) are frequently detected in anti-neutrophil cytoplasm antibodies (ANCA)-associated systemic vasculitis (AAV) and are considered to play pathological roles but their…
Abstract Number: 860 • 2012 ACR/ARHP Annual Meeting
Interleukin-21, B Cell Activating Factor and Unmethylated CpG Oligodeoxynucleotides Synergize in Promoting Anti-Proteinase 3 Autoantibody Production in Vitro
Nikola Lepse¹, Judith Land², Abraham Rutgers², Cees G.M. Kallenberg², Coen A. Stegeman³, Peter Heeringa¹ and Wayel H. Abdulahad², ¹Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Nephrology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are characterized by the presence of circulating autoantibodies that are often directed against proteinase 3 (PR3). Although the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].